Caris Life Sciences Inc(US:CAI) Prnewswire·2026-02-26 21:05Core Insights - Caris Life Sciences reported a significant revenue growth of 97% for the full year 2025, driven by strong performance in molecular profiling services [1] - The company expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, indicating a growth of approximately 23% to 26% compared to 2025 [1] Financial Highlights - Fourth Quarter 2025 total revenue was $292.9 million, a 125% increase from $129.9 million in Q4 2024, primarily due to a 199% growth in molecular profiling services revenue [1][3] - Full Year 2025 total revenue reached $812.0 million, up from $412.3 million in 2024, with molecular profiling services revenue growing by 120% to $766.7 million [1][3] - Gross margin improved to 75% in Q4 2025 from 54% in Q4 2024, and for the full year, it was 66%, up from 43% in 2024 [1][3] Operating Performance - The company completed approximately 52,700 clinical therapy selection cases in Q4 2025, a 20% increase year-over-year, and around 199,300 cases for the full year, a 22% increase [1] - Positive net cash provided by operating activities was $44.8 million in Q4 2025, compared to a net cash used of $38.9 million in Q4 2024, marking a 215% improvement [1][3] Future Outlook - Caris anticipates clinical therapy selection volume to grow approximately 20% in 2026 compared to 2025 [1] - The company announced a collaboration with Genentech to discover novel therapeutic targets in cancers with high unmet clinical need [1]